Premium
The PAI‐1 4G/5G and ACE I/D Polymorphisms and Risk of Recurrent Pregnancy Loss: A Case–Control Study
Author(s) -
Kim Jin Ju,
Choi Young Min,
Lee Sung Ki,
Yang Kwang Moon,
Paik Eun Chan,
Jeong Hyeon Jeong,
Jun Jong Kwan,
Han Ae Ra,
Hong Min A
Publication year - 2014
Publication title -
american journal of reproductive immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.071
H-Index - 97
eISSN - 1600-0897
pISSN - 1046-7408
DOI - 10.1111/aji.12302
Subject(s) - genotyping , genotype , plasminogen activator inhibitor 1 , medicine , angiotensin converting enzyme , plasminogen activator , case control study , pregnancy , endocrinology , taqman , thrombophilia , gastroenterology , biology , genetics , thrombosis , polymerase chain reaction , gene , blood pressure
Problem Thrombophilia has been postulated to be a contributor to the pathophysiology of recurrent pregnancy loss (RPL). We investigated the role of the plasminogen activator inhibitor type 1 (PAI‐1) 4G/5G and angiotensin converting enzyme (ACE) I/D polymorphisms in Korean patients with RPL. Method of study Genotyping was performed using the TaqMan assay in 227 RPL patients and 304 controls. Results The genotype distributions of both polymorphisms in the RPL group did not differ from those of controls. Because the frequency of being homozygous for ACE D/D and the PAI‐I 4G/4G combination has been reported to be significantly higher in RPL patients, this was also analyzed. However, no significant difference was noted; 3.1% of RPL patients had both ACE D/D and PAI‐I 4G/4G, as did 4.9% of controls ( P = 0.791). Conclusion The current study suggests that both polymorphisms, either alone or in combination, are not major determinants of the development of RPL in Korean women.